产品
编 号：F342666
分子式：C12H10O7V
分子量：317.15
分子式：C12H10O7V
分子量：317.15
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
320
In-stock
10mg
480
In-stock
25mg
960
In-stock
50mg
1536
In-stock
100mg
2331
In-stock
结构图
CAS No: 38213-69-3
产品详情
生物活性：
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.
体内研究：
Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice.Animal Model:C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD)
Dosage:0.75-3.0 mmol
Administration:Intraperitoneal injection; twice weekly; for 6 weeks
Result:Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
体外研究：
Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.
体内研究：
Bis(maltolato)oxovanadium(IV) (BMOV; 0.75-3.0 mmol; intraperitoneal injection; twice weekly; for 6 weeks; C57BL/6J mice) treatment ameliorates the metabolic phenotype. Liver, skeletal muscle, and adipose tissue revealed a significantly reduced PTP activity in all analysed tissues compared to HFD mice.Animal Model:C57BL/6J mice (4-6 weeks) fed with high-fat diet (HFD)
Dosage:0.75-3.0 mmol
Administration:Intraperitoneal injection; twice weekly; for 6 weeks
Result:Ameliorated the metabolic phenotype, as evidenced by reduced body weight, improved insulin sensitivity and glucose tolerance.
体外研究：
Bis(maltolato)oxovanadium(IV) treatment enhances the phosphorylation of the insulin receptor and of the insulin signalling key intermediate Akt. Bis(maltolato)oxovanadium(IV) (BMOV; 50 μM) treatment also resultes in an increased glucose uptake in C2C12 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备